

GAVI/2014/71/dlc

The Minister of Health and Labour
Ministry of Health and Labour
Brickdam
Georgetown
Guyana

11 December 2014

Dear Minister,

Decision Letter: Request for 2015 Renewal of Gavi support for New Vaccines Support

I am writing in relation to Guyana's request for renewal for New Vaccines Support (NVS) for Rotavirus and Pneumococcal vaccines, which was reviewed by the Gavi High Level Review Panel (HLRP) on 27-29 October 2014.

Following the recommendations made by the Panel, I am pleased to inform you that Gavi has approved Guyana for support for new vaccines, as specified in the Appendices to this letter.

In addition to the renewal decision that has been outlined above, we would also like to draw your attention to the recommendations of the HLRP and the action points it endorsed.

The Internal Appraisal, as endorsed by the HLRP, has noted the following recommended areas for action. We encourage you to work to ensure these points are adequately addressed. We request that you review these action points and revert to us with proposed arrangements to address them. I would be happy to have a discussion on these comments at your earliest convenience should this be helpful.

- To finalize and implement the 2013 EVM improvement plan recommendations.
- To ensure robust reporting systems and data quality.
- To consider how to strengthen its AEFI and surveillance systems.
- To develop a mechanism for gathering gender desegregated data.
- To ensure more robust involvement of CSOs at all levels including possible expansion at ICC level.
- Should strengthen partnerships with EPI and scale up Communication for Development (C4D) for future introductions of new vaccines.

Guyana received a Partnership Framework Agreement (PFA) in April 2014. To date, we have not received the signatures of the Ministry of Health and Ministry of Finance on the PFA. Please be advised that until that Agreement has been signed between

Gavi and Guyana, Gavi will not process any further applications (for HSS and new vaccine support) that the Independent Review Committee has recommended for approval and will no longer disburse subsequent tranches of Health System Strengthening and/or Immunisation Services Support funds that were approved earlier.

The Appendices includes the following important information:

Appendix A: Description of approved Gavi support to Guyana


Appendix B: Financial and programmatic information per type of support

Appendix C: Internal Appraisal Report

Appendix D: The terms and conditions of Gavi support.

Please do not hesitate to contact my colleague Homero Hernandez (hhernandez@gavi.org) if you have any questions or concerns.

Yours sincerely,



Hind Khatib-Othman
Managing Director, Country Programmes

cc: The Minister of Finance
 The Director of Medical Services
 Director Planning Unit, MoH
 The EPI Manager
 WHO Country Representative
 UNICEF Country Representative
 Regional Working Group
 WHO HQ
 UNICEF Programme Division
 UNICEF Supply Division
 The World Bank

Description of Gavi support to Guyana (the “Country”)

New Vaccines Support (NVS)

Gavi, The Vaccine Alliance has approved the Country’s request for supply of vaccine doses and related injection safety material which are estimated to be required for the immunization programme as set out in Appendix B. Financing provided by Gavi for vaccines will be in accordance with:

- The Gavi Guidelines governing Guyana’s proposal application; and
- The final proposal as approved by the Independent Review Committee (IRC), including any subsequent clarifications.

The vaccines provided will be used as the country has proposed. The principles of the WHO-UNICEF-UNFPA joint statement on safety of injections (WHOM&B/99.25) shall apply to all immunisation provided with these vaccines.

Item number 11 of Appendix B summarises the details of the approved Gavi support for vaccines in the years indicated.

Any required taxes, customs, toll or other duties imposed on the importation of vaccines and related supplies can not be paid for using Gavi funds.

The Country shall be solely responsible for any liability that may arise in connection with: (i) the implementation of any programmes in the Country; and (ii) the use or distribution of vaccines and related supplies after title to such supplies has passed to the Country. Gavi shall not be responsible for providing any additional funding to replace any vaccines and related supplies that are, or became, defective or disqualified for whatever reason.

Country Co-financing

In accordance with the Gavi Co-financing Policy, the Country has agreed to make the required contribution to co-financing vaccine doses as indicated in Appendix B. Item number 14 of Appendix B summarises the budget and the quantity of supply that will be procured with country’s funds in the corresponding timeframe. The total co-financing amount indicates costs for the vaccines, related injection safety devices (only applicable to intermediate and graduating countries) and freight.

Countries may select to co-finance through UNICEF Supply Division, PAHO’s Revolving Fund, or self-procure their co-financing requirement following their own procedures, except for the Pneumococcal vaccine that needs to be procured through UNICEF.

If the purchase of the co-financed supply is carried out through UNICEF or PAHO, the payment is to be made to UNICEF or PAHO (whichever is applicable) as agreed in the Procurement Services Memorandum of Understanding between UNICEF or agreements between PAHO (whichever is applicable) and the Country, and not to Gavi. Please keep in contact with UNICEF or PAHO (whichever is applicable) to understand the availability of the relevant vaccine(s) and to prepare the schedule of deliveries.

The total co-financing amount expressed in item number 14 of Appendix B does not contain costs and fees of the relevant Procurement Agency, such as contingency buffer and handling fees.

Information on these extra costs and fees will be provided by the relevant Procurement Agency as part of the cost estimate to be requested by the Country. UNICEF/PAHO will share information with Gavi on the status of purchase of the co-financed supply. In accordance with the Gavi Co-financing Policy (<http://www.gavi.org/about/governance/programme-policies/co-financing/>), the co-financing contribution is payable annually to UNICEF/PAHO.

If the purchase of the co-financed supply is carried out by the Government, following its own procurement procedures and not procuring from UNICEF Supply Division or PAHO's Revolving Fund, the Government must submit to Gavi satisfactory evidence that it has purchased its co-financed portion of the vaccines and related supplies, including by submitting purchase orders, invoices, and receipts to Gavi. Gavi encourages that countries self-procuring co-financed products (i.e. auto-disable syringes and syringe and needle disposal boxes) ensure that products appear on the applicable WHO list of pre-qualified products or, for syringe and needle disposal boxes, that they have obtained a certificate of quality issued by a relevant national authority.

Gavi support will only be provided if the Country complies with the following requirements:

Transparency and Accountability Policy(TAP): Compliance with any TAP requirements pursuant to the Gavi TAP Policy and the requirements under any Aide Memoire concluded between Gavi and the Country.

Financial Statements & External Audits: Compliance with the Gavi requirements relating to financial statements and external audits.

Grant Terms and Conditions: Compliance with Gavi's standard grant terms and conditions (attached in Appendix D).

Country Co-financing: Gavi must receive proof of country co-payment from the Country such as invoices or shipment receipts if neither UNICEF nor PAHO is the procurement agent for country co-financed vaccine for the prior calendar year.

Monitoring and Annual Progress Reports or equivalent: Country's use of financial support for the introduction of new vaccinations with the vaccine(s) specified in Appendix B is subject to strict performance monitoring. Gavi uses country systems for monitoring and auditing performance and other data sources including WHO/UNICEF immunisation coverage estimates. As part of this process, National Authorities will be requested to monitor and report on the numbers of children immunised and on co-financing of the vaccine.

Country will report on the achievements and request support for the following year in the Annual Progress Report (APR) or equivalent. The APR or equivalent must contain information on the number of children reported to have been vaccinated with DTP3 and 3 doses of pentavalent vaccine by age 12 months, based on district monthly reports reviewed by the Immunisation Coordination Committee (ICC), and as reported to WHO and UNICEF in the annual Joint Reporting Form (JRF). The APRs or equivalent will also contain information on country's compliance with the co-financing arrangements outlined in this letter. APRs or equivalent endorsed by the ICC, should be sent to the Gavi Secretariat no later than 15 May every year. Continued funding beyond what is being approved in this letter is conditional upon receipt of satisfactory Annual Progress Reports or equivalent and availability of funds.

Guyana VACCINE SUPPORT
Apoyo para vacunas a Guyana

This Decision Letter sets out the Programme Terms of a Programme.

En la presente Carta de Decisión se exponen los Términos del Programa

1. Country: Guyana <i>País</i>			
2. Grant Number: 1015-GUY-12c-X <i>Número de subvención:</i>			
3. Date of Decision Letter: 11/12/2014 <i>Fecha de Carta de Decisión:</i>			
4. Date of the Partnership Framework Agreement: Not applicable <i>Fecha del Acuerdo Marco de Alianza:</i>			
5. Programme Title: NVS, Pneumococcal Routine <i>Título del Programa:</i>			
6. Vaccine type: Pneumococcal <i>Tipo de vacuna:</i>			
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV13), 1 dose(s) per vial , LIQUID <i>Presentación solicitada del producto y fórmula de la vacuna:</i>			
8. Programme Duration¹: 2010 - 2015 <i>Duración del programa:</i>			
9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement): <i>Presupuesto del programa (indicativo) (sujeto a los términos del Acuerdo Marco de Alianza):</i>			
	2010-2014	2015	Total ²
Programme Budget (US\$) <i>Presupuesto del Programa (US\$)</i>	US\$1,105,308 ³	US\$67,500	US\$1,172,808
10. Vaccine Introduction Grant: Not applicable <i>Asignación para introducción de vacunas:</i>			

¹ This is the entire duration of the programme. *Esta es toda la duración del Programa*

² This is the total amount endorsed by GAVI for the entire duration of the programme. This should be equal to the total of all sums in the table. *Este es el monto total aprobado por GAVI para la duración total del programa y debe ser igual al total de todas las sumas incluidas en el cuadro.*

³ This is the consolidated amount for all previous years. *Este es el monto consolidado de todos los años anteriores.*

11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):⁴

Montos anuales indicativos (sujetos a las condiciones del Acuerdo marco de Alianza):

Type of supplies to be purchased with GAVI funds in each year <i>Tipo de insumos que se comprarán con los fondos GAVI en cada año</i>	2010-2014	2015
Number of Pneumococcal vaccines doses <i>Número de dosis de vacunas</i>		10,800
Number of AD syringes <i>Número de jeringas autodesactivables (AD)</i>		12,300
Number of re-constitution syringes <i>Número de jeringas de reconstitución</i>		
Number of safety boxes <i>Número de cajas de seguridad</i>		150
Annual Amounts (US\$) <i>Cantidad anual (US\$)</i>	US\$1,105,308 ⁵	US\$67,500

12. Procurement agency: PAHO. The Country shall release its Co-Financing Payments each year to PAHO.

Organismo de adquisición: OPS. El país hará sus pagos de cofinanciamiento anualmente a la OPS.

13. Self-procurement: Not applicable.

Adquisición por cuenta propia: No corresponde

14. Co-financing obligations: Reference code: 1015-GUY-12c-X-C According to the Co-Financing Policy, the Country falls within the group Graduating. The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Obligaciones de cofinanciamiento: Código de referencia : [1015-GUY-12c-X-C] Conforme a la política de cofinanciamiento, el país se inscribe en el grupo en vía de graduación. La tabla siguiente resume el pago de cofinanciamiento y la cantidad de insumos que se adquirirán con dichos fondos en el año correspondiente.

Type of supplies to be purchased with Country funds in each year <i>Tipo de insumos que se adquirirán con fondos de GAVI en cada año</i>	2015
Number of vaccine doses <i>Número de dosis de vacunas</i>	32,400
Number of AD syringes <i>Número de jeringas autodesactivables</i>	32,200
Number of re-constitution syringes <i>Número de jeringas de reconstitución</i>	

⁴ This is the amount that GAVI has approved. *Este es el monto aprobado por GAVI.*

⁵ This is the consolidated amount for all previously approved years. *Este es el monto consolidado de todos los años aprobados precedentemente.*

Number of safety boxes <i>Número de cajas de seguridad</i>	375
Value of vaccine doses (US\$) <i>Precio de dosis de vacunas (US\$)</i>	US\$105,557
Total Co-Financing Payments (US\$) (including freight) <i>Cofinanciamiento total (US\$) (incluye costos de flete)</i>	US\$114,000
15. Operational support for campaigns: Not applicable <i>Apoyo operativo para campañas:</i>	
16. Additional documents to be delivered for future disbursements: Not applicable <i>Documentos que deberán presentarse para desembolsos futuros</i>	
Reports, documents and other deliverables <i>Informes, documentos y otros instrumentos</i>	Due dates <i>Fecha límite de recepción</i>
Annual Progress Report 2014	As agreed with the Gavi Secretariat
17. Financial Clarifications: The Country shall provide the following clarifications to GAVI*: <i>*Failure to provide the financial clarifications requested may result in GAVI withholding further disbursements</i> <i>Aclaraciones financieras: El país deberá suministrar las siguientes aclaraciones a GAVI*:</i> <i>* La falta de respuesta a las aclaraciones financieras podrá dar lugar a que GAVI retenga desembolsos futuros</i>	
18. Other conditions: Not applicable. <i>Otras condiciones:: No corresponde.</i>	

Signed by / *Firmado por*

On behalf of the GAVI Alliance/ *En representación de GAVI Alliance*



Hind Khatib-Othman

Managing Director, Country Programmes/ *Directora Gerente, Programas en los países*

11 December 2014

Guyana VACCINE SUPPORT
Apoyo para vacunas a Guyana

This Decision Letter sets out the Programme Terms of a Programme.

En la presente Carta de Decisión se exponen los Términos del Programa

19. Country: Guyana <i>Pais</i>			
20. Grant Number: 0815-GUY-13b-X <i>Número de subvención:</i>			
21. Date of Decision Letter: 11/12/2014 <i>Fecha de Carta de Decisión:</i>			
22. Date of the Partnership Framework Agreement: Not applicable <i>Fecha del Acuerdo Marco de Alianza:</i>			
23. Programme Title: NVS, Rotavirus Routine <i>Título del Programa:</i>			
24. Vaccine type: Rotavirus <i>Tipo de vacuna:</i>			
25. Requested product presentation and formulation of vaccine: Rotavirus, 2 dose(s) schedule <i>Presentación solicitada del producto y fórmula de la vacuna:</i>			
26. Programme Duration⁶: 2009 - 2015 <i>Duración del programa:</i>			
27. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement): <i>Presupuesto del programa (indicativo) (sujeto a los términos del Acuerdo Marco de Alianza):</i>			
	2009-2014	2015	Total ⁷
Programme Budget (US\$) <i>Presupuesto del Programa (US\$)</i>	US\$1,277,500 ⁸	US\$4,000	US\$1,281,500
28. Vaccine Introduction Grant: Not applicable <i>Asignación para introducción de vacunas:</i>			

⁶ This is the entire duration of the programme. *Esta es toda la duración del Programa*

⁷ This is the total amount endorsed by GAVI for the entire duration of the programme. This should be equal to the total of all sums in the table. *Este es el monto total aprobado por GAVI para la duración total del programa y debe ser igual al total de todas las sumas incluidas en el cuadro.*

⁸ This is the consolidated amount for all previous years. *Este es el monto consolidado de todos los años anteriores.*

29. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):⁹

Montos anuales indicativos (sujetos a las condiciones del Acuerdo marco de Alianza):

Type of supplies to be purchased with GAVI funds in each year <i>Tipo de insumos que se comprarán con los fondos GAVI en cada año</i>	2009-2014	2015
Number of Rotavirus vaccines doses <i>Número de dosis de vacunas</i>		0
Number of AD syringes <i>Número de jeringas autodesactivables (AD)</i>		
Number of re-constitution syringes <i>Número de jeringas de reconstitución</i>		
Number of safety boxes <i>Número de cajas de seguridad</i>		
Annual Amounts (US\$) <i>Cantidad anual (US\$)</i>	US\$1,277,500 ¹⁰	US\$4,000

30. Procurement agency: PAHO. The Country shall release its Co-Financing Payments each year to PAHO.

Organismo de adquisición: OPS - El país hará sus pagos de cofinanciamiento anualmente a la OPS.

31. Self-procurement: Not applicable.

Adquisición por cuenta propia: No corresponde

32. Co-financing obligations: Reference code: 0815-GUY-13b-X-C. According to the Co-Financing Policy, the Country falls within the group Graduating.

The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Obligaciones de cofinanciamiento: Código de referencia : 0815-GUY-13b-X-C. Conforme a la política de cofinanciamiento, el país se inscribe en el grupo en vía de graduación. La tabla siguiente resume el pago de cofinanciamiento y la cantidad de insumos que se adquirirán con dichos fondos en el año correspondiente.

Type of supplies to be purchased with Country funds in each year <i>Tipo de insumos que se adquirirán con fondos de GAVI en cada año</i>	2015
Number of vaccine doses <i>Número de dosis de vacunas</i>	34,500
Number of AD syringes <i>Número de jeringas autodesactivables</i>	
Number of re-constitution syringes	


⁹ This is the amount that GAVI has approved. *Este es el monto aprobado por GAVI.*

¹⁰ This is the consolidated amount for all previously approved years. *Este es el monto consolidado de todos los años aprobados precedentemente.*

Número de jeringas de reconstitución	
Number of safety boxes <i>Número de cajas de seguridad</i>	
Value of vaccine doses (US\$) <i>Precio de dosis de vacunas (US\$)</i>	US\$84,669
Total Co-Financing Payments (US\$) (including freight) <i>Cofinanciamiento total (US\$) (incluye costos de flete)</i>	US\$88,000
33. Operational support for campaigns: Not applicable <i>Apoyo operativo para campañas: no corresponde</i>	
34. Additional documents to be delivered for future disbursements: <i>Documentos que deberán presentarse para desembolsos futuros</i>	
Reports, documents and other deliverables <i>Informes, documentos y otros instrumentos</i>	Due dates <i>Fecha límite de recepción</i>
<i>Annual Progress Report 2014</i>	As agreed with the Gavi Secretariat
35. Financial Clarifications: The Country shall provide the following clarifications to GAVI*: Not applicable <i>*Failure to provide the financial clarifications requested may result in GAVI withholding further disbursements</i> <i>Aclaraciones financieras: El país deberá suministrar las siguientes aclaraciones a GAVI*:</i> <i>* La falta de respuesta a las aclaraciones financieras podrá dar lugar a que GAVI retenga desembolsos futuros</i>	
36. Other conditions: Not applicable. <i>Otras condiciones:: No corresponde.</i>	

Signed by / *Firmado por*

On behalf of the GAVI Alliance/ *En representación de GAVI Alliance*



Hind Khatib-Othman

Managing Director, Country Programmes/ *Directora Gerente, Programas en los países*

11 December 2014

Guyana Internal Appraisal 2014

1. Brief Description of Process

This Appraisal was developed by Technical Expert, Assad Hafeez in collaboration with Gavi's Senior Country Manager (SCM) for Guyana. It is based on the 2013 APR submitted by the country, and related documentation.

2. Achievements and Constraints

Guyana has made considerable progress in achieving the overall goals and objectives of its programme in the last years. There is strong political commitment at highest echelons and health leadership level towards immunization services, depicted by keen involvement of all the government officials in the respective processes and fulfilment of financial commitments by the state. The country has been putting in efforts in implementing strategies to improve and maintain the immunization coverage in all the ten administrative regions. The hard to reach populations of hinterlands have also been addressed by enhancing resources for community awareness programs in the regions. The national cold room functions effectively and some new equipment has been added. Vaccination week of the Americas 2013 had various successful activities in remote areas along with mop up campaigns in remote hinterland areas. EPI trainings were conducted in all regions successfully.

2013 coverage targets show satisfactory achievements and the country has gone beyond the set targets in certain areas. BCG coverage is 96% against target of 95%, DTP3 coverage is 98% against 95%, Rota virus is 96% against 97% and PCV13 is 96% against the target of 97%. Measles coverage is given as 96% whereas TT coverage is 99%. Wastage rates in general have been contained and drop outs were well below the expected rates of 7%. Reported coverage is based on JRF data and APR or accompanying documents do not give any conflicting results from any other data source.

The review of documents suggests that there is cognisance of the challenges being faced in areas of human resource, trainings and service delivery in hinterland regions. Gender disaggregated data are not routinely available however there are plans to collect such information in future. The report does not give much information on equity issues. This is of concern particularly in hard to reach and sparsely populated hinterland regions.

3. Governance

The various governing tiers are in place for overseeing GAVI related projects. The level and seniority of participation is as per prescribed criteria and appropriate, including senior officials from the ministry and representatives from international organisations. However, representation from other line ministries, civil society and related sectors is not prominent. ICC and technical committees meet frequently and discuss issues related to APR. The ICC met 3 times in 2013 and twice in 2014. The critical issues like annual targets, financial

reports, gender equity, reaching out to underserved communities, new vaccines and surveillance systems have been discussed here thoroughly.

The participation of CSOs is not prominent and only one organisation (Rotary International) is on board which also has not participated in the proceedings of ICC meetings this year. This is an area where further progress could help improve the quality and transparency of the systems.

Additional comments from UNICEF proposed that great involvement of CSOs would create buy-in, especially in the area of “A Promise Renewed”.

4. Programme Management

The MoH has a five year strategic health plan and annual work plans with defined goals and objectives at national and regional levels. The baseline and future targets are realistic as reported in APR and evidence of evaluation/reviews is available in the attached documents. The current management arrangement has been successfully implementing earlier grants including ISS and NVS within expected timelines. The EPI is integrated into the routine child health program. The ten regions have varying capacity and 4 hinterland regions are particularly challenging in terms of their sparse and widespread population. In the evaluation carried out over the last year the variance in capacity has been specifically highlighted and remedial measures have been suggested.

The cMYP was revised up to 2015 from its original end year of 2012. No indication of plans to update next year. This will need to be provided as part of the application requirements for receiving support from Gavi for IPV introduction support.

5. Programme Delivery

In Guyana various modalities are adopted to provide services including fixed post vaccination, community outreach, school vaccination and home visits. New vaccines have been introduced through this multiple tiered program and Guyana has shown fairly good results. The last immunization program assessment was carried out in 2013. Most scores were above 90 % with Human and Physical resource scoring the minimum (47%) due to insufficient HR at all levels in public sector. Other areas as vaccine safety, training & supervision and cold chain scored satisfactorily with some identified areas for further improvements. The progress report shows that all of the weak areas have been addressed or in the process of improvement.

The country has an injection safety plan however incinerators are not available in every facility and the medical waste is transported to a central locations for disposal. The waste disposal system does need further improvement and strengthening. There is an AEFI system as reported in the APR. The reports are discussed in the technical committee meetings and shared with other countries. A sentinel surveillance system for rotavirus diarrhoea exists and the country conducts special studies on this issue, however no such mechanism is in place for pneumococcal disease.

6. Data Quality

The JRF DTP3 coverage estimates are 98%in 2013 as compared to the target of 95%. No coverage survey has been done in the last years and administrative data is the only available source for all the current figures. The quality of coverage data is ensured by

various measures as reported in APR. On receipt of the regional data this is checked and verified by the nursing officer before this is tabulated. The date and time on which it is noted is also stamped by the nurse. Three EPI meetings are held each year where this is discussed and corrections made. Feedback information is provided to the regions on the national and regional immunization coverage. In order to further improve the data quality, new EPI monitoring tools have been prepared and are currently being used in the regions. The tool provides guidelines on the process of data input, flow and feedback. Data quality and information management system is one of the areas which will require further strengthening.

7. Financial Management

The GAVI PFA has not been signed yet, although there have been increasing communications with the government preparing a response with comments to negotiate signatures in September. The GAVI funds were managed by PAHO/WHO which has its own financial systems, as per regulations of PAHO and the international Public Sector Accounting Standards (IPAS), in addition to internal and external audits. Expenditures of GAVI funds are carried out in accordance to the ICC approved work plan. ISS funds carried forward from 2012 were used in social mobilization activities in remote hinterland areas after approval from competent authority. The accompanying documents do not show any external audits of the EPI program and they are not receiving any HSS funds.

8. NVS Targets

The country is estimating to vaccinate 13,776 and 13,790 children with PCV13 and rota virus vaccine respectively. Wastage and dropout rates of 5% and 2% are acceptable with a good track record in both the areas by the country program. The possible issues in NVS area will be approaching the remote regions, disparity among services in various regions and better data quality. The lack of human resources for health at peripheral levels is a major obstacle to further improve coverage and the ability to sustain existing levels of coverage.

The request for NVS for PCV13 and Rota virus is planned for 2015. The Rota virus dosage has been modified to 2 doses instead of 3 doses as per the recommendations of technical advisory committee. The committee recommended this in light of issues with vaccine presentation availability from manufacturers through the regional procurement mechanism (PAHO Revolving Fund). The adjustments in the birth cohort estimations and revision of targets have been made on the advice of GAVI in the proposed request. Guyana has introduced HPV in 4 regions and plans to expand to 3 more depending on the availability of the vaccine, but they have not received Gavi support for the introduction.

9. EPI Financing and Sustainability

The government has fulfilled its budgetary commitments as per GAVI's requirements. There is an incremental increase in the co-financing in the new vaccine category, traditional vaccines are funded by the government itself and there is adequate budgetary allocation for immunization in the health budget. While indication point to continued success and good performance of the EPI programme, as a graduating country, Guyana's future success will be highly dependent on the governments's ability to continue to prioritize its programme. To support the government sustain its achievements, a joint graduation assessment visit is planned to take place in late October where a transition plan will be developed.

10. Renewal Recommendations

Topic	Recommendation
NVS	<ul style="list-style-type: none"> • PCV13: renewal of support • Rotavirus: renewal of support

11. Other Recommended Actions

Topic	Action Point
	<ul style="list-style-type: none"> • The country to take action to finalize and implement the 2013 EVM improvement plan recommendations. • The country to ensure robust reporting systems and data quality. • The country to consider how to strengthen its AEFI and surveillance systems. • The country to develop mechanism for gathering gender desegregated data. • The country to ensure more robust involvement of CSOs at all levels including possible expansion at ICC level. • Should strengthen partnerships with EPI and scale up C4D for future introductions of new vaccines.

Appendix D

Gavi Terms and Conditions

Countries will be expected to sign and agree to the following Gavi terms and conditions in the application forms, which may also be included in a grant agreement to be agreed upon between Gavi and the country:

FUNDING USED SOLELY FOR APPROVED PROGRAMMES

The applicant country (“Country”) confirms that all funding provided by Gavi for this application will be used and applied for the sole purpose of fulfilling the programme(s) described in this application. Any significant change from the approved programme(s) must be reviewed and approved in advance by Gavi. All funding decisions for this application are made at the discretion of the Gavi Board and are subject to IRC processes and the availability of funds.

AMENDMENT TO THIS PROPOSAL

The Country will notify Gavi in its Annual Progress Report if it wishes to propose any change to the programme(s) description in this application. Gavi will document any change approved by Gavi, and this application will be amended.

RETURN OF FUNDS

The Country agrees to reimburse to Gavi, all funding amounts that are not used for the programme(s) described in this application. The country’s reimbursement must be in US dollars and be provided, unless otherwise decided by Gavi, within sixty (60) days after the Country receives Gavi’s request for a reimbursement and be paid to the account or accounts as directed by Gavi.

SUSPENSION/ TERMINATION

Gavi may suspend all or part of its funding to the Country if it has reason to suspect that funds have been used for purpose other than for the programmes described in this application, or any Gavi-approved amendment to this application. Gavi retains the right to terminate its support to the Country for the programmes described in this application if a misuse of Gavi funds is confirmed.

ANTICORRUPTION

The Country confirms that funds provided by Gavi shall not be offered by the Country to any third person, nor will the Country seek in connection with this application any gift, payment or benefit directly or indirectly that could be construed as an illegal or corrupt practice.

AUDITS AND RECORDS

The Country will conduct annual financial audits, and share these with Gavi, as requested. Gavi reserves the right, on its own or through an agent, to perform audits or other financial management assessment to ensure the accountability of funds disbursed to the Country.

The Country will maintain accurate accounting records documenting how Gavi funds are used. The Country will maintain its accounting records in accordance with its

government-approved accounting standards for at least three years after the date of last disbursement of Gavi funds. If there is any claims of misuse of funds, the Country will maintain such records until the audit findings are final. The Country agrees not to assert any documentary privilege against Gavi in connection with any audit.

CONFIRMATION OF LEGAL VALIDITY

The Country and the signatories for the government confirm that this application is accurate and correct and forms a legally binding obligation on the Country, under the Country's law, to perform the programmes described in this application.

CONFIRMATION OF COMPLIANCE WITH GAVI TRANSPARENCY AND ACCOUNTABILITY POLICY

The Country confirms that it is familiar with Gavi Transparency and Accountability Policy (TAP) and will comply with its requirements.

ARBITRATION

Any dispute between the Country and Gavi arising out of or relating to this application that is not settled amicably within a reasonable period of time, will be submitted to arbitration at the request of either Gavi or the Country. The arbitration will be conducted in accordance with the then-current UNCITRAL Arbitration Rules. The parties agree to be bound by the arbitration award, as the final adjudication of any such dispute. The place of arbitration will be Geneva, Switzerland. The language of the arbitration will be English.

For any dispute for which the amount at issue is US\$ 100,000 or less, there will be one arbitrator appointed by Gavi. For any dispute for which the amount at issue is greater than US \$100,000 there will be three arbitrators appointed as follows: Gavi and the Country will each appoint one arbitrator, and the two arbitrators so appointed will jointly appoint a third arbitrator who shall be the chairperson.

Gavi will not be liable to the country for any claim or loss relating to the programmes described in this application, including without limitation, any financial loss, reliance claims, any harm to property, or personal injury or death. The Country is solely responsible for all aspects of managing and implementing the programmes described in this application.

USE OF COMMERCIAL BANK ACCOUNTS

The eligible country government is responsible for undertaking the necessary due diligence on all commercial banks used to manage Gavi cash-based support, including HSS, ISS, CSO and vaccine introduction grants. The undersigned representative of the government confirms that the government will take all responsibility for replenishing Gavi cash support lost due to bank insolvency, fraud or any other unforeseen event.

